Evidence map›Paper›PMID 41868134›Full record

ArticleFrontiers in pharmacology2026

Sex-related pharmacokinetic and pharmacological responses to 4F-furanylfentanyl.

Sabrine Bilel, Camilla Montesano, Micaela Tirri, Giorgia Corli, Marta Bassi, Nicole Cocita, Fabiana Di Rosa, Adolfo Gregori, Claudio Trapella, Manuel Sergi and 1 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sabrine Bilel *Department of Translational Medicine, Section of Legal Medicine and LTTA Centre and University Center of Gender Medicine, University of Ferrara, Ferrara, Italy.
Camilla Montesano *Department of Chemistry, Sapienza University of Rome, Rome, Italy.
Micaela TirriDepartment of Translational Medicine, Section of Legal Medicine and LTTA Centre and University Center of Gender Medicine, University of Ferrara, Ferrara, Italy.
Giorgia CorliDepartment of Translational Medicine, Section of Legal Medicine and LTTA Centre and University Center of Gender Medicine, University of Ferrara, Ferrara, Italy.
Marta BassiDepartment of Translational Medicine, Section of Legal Medicine and LTTA Centre and University Center of Gender Medicine, University of Ferrara, Ferrara, Italy.
Nicole CocitaDepartment of Translational Medicine, Section of Legal Medicine and LTTA Centre and University Center of Gender Medicine, University of Ferrara, Ferrara, Italy.
Fabiana Di RosaCarabinieri, Department of Scientific Investigation (RIS), Rome, Italy.
Adolfo GregoriCarabinieri, Department of Scientific Investigation (RIS), Rome, Italy.
Claudio TrapellaDepartment of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy.
Manuel SergiDepartment of Chemistry, Sapienza University of Rome, Rome, Italy.
Matteo MartiDepartment of Translational Medicine, Section of Legal Medicine and LTTA Centre and University Center of Gender Medicine, University of Ferrara, Ferrara, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Novel synthetic opioids (NSOs), including a variety of fentanyl analogs (FAs) and emerging non-fentanyl compounds, have increasingly been implicated in overdose fatalities worldwide. Among these, 4-fluoro-furanylfentanyl (4F-FUF) is a potent FA with limited Methods: Female and male mice were injected intraperitoneally with 4F-FUF at an effective dose of 5 mg/kg. Behavioral and physiological responses, including sensorimotor, motor, and respiratory parameters, were assessed at multiple timepoints post-administration. Plasma and tissue samples (brain, heart, liver, spleen, lung, kidney, and stomach) were collected to determine 4F-FUF concentrations and pharmacokinetic parameters. Correlations between plasma levels and behavioral or physiological outcomes were analyzed separately by sex. Results: 4F-FUF impaired the sensorimotor and motor responses in females and males. Moreover, the FA induced persistent antinociception in males with respect to females. The respiratory depression was sudden and more pronounced in male mice. Plasma concentrations of 4F-FUF were higher and persisted longer in males, indicating slower clearance than in females. This drug was highly distributed in the brain and liver tissues of both sexes. Significant correlations were detected in visual placing, vibrissae responses, spontaneous locomotion, and mechanical analgesia in both sexes. Interestingly, the respiratory rate was only significantly correlated with plasma concentrations in females, highlighting potential sex-specific differences in the relationship between drug exposure and physiological effects. Conclusion: The findings demonstrate marked sex-specific differences in the behavioral and physiological changes and pharmacokinetics of 4F-FUF. These results underscore the importance of considering sex-specific differences in assessing the toxicity and risk profiles of novel synthetic opioids.

Indexed as

fentanylfentanyl analogsnovel psychoactive substancesnovel synthetic opioidspharmacokineticsrespiratory depressionsex-specific differencesμ-opioid receptor

Identifiers

PMID41868134
PMCPMC13002593

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.